Ensemble Therapeutics has entered a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals to discover Macrocycle drug candidates targeting severe and ultra-rare disorders. Ensemble will screen its Ensemblin collection of more than 10 million macrocycles against several disease targets specified by Alexion, in order to discover new small molecule clinical candidates. Alexion will have the exclusive worldwide rights to develop and commercialize candidates arising from the colla...